News
Categories
Sign up
Featured Posts
Archive
- September 2020
- June 2020
- April 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- May 2018
- April 2018
- March 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- July 2017
- May 2017
- April 2017
- February 2017
- January 2017
Follow Us
JERUSALEM (Reuters) - Israeli medical device maker Alpha Tau Medical said on Thursday it raised $26 million in a funding round from investors including Shavit Capital, Medison Ventures and OurCrowd to help finance global clinical trials. Alpha Tau said it has successfully completed its first-in-human clinical trial of Alpha DaRT — a radiation cancer therapy — with squamous cell carcinoma patients from Italy and Israel. It is now conducting trials in other sites, such as its first U.S. trial at Memorial Sloan Kettering Cancer Center in New York, a pancreatic cancer trial at CHUM in Montreal and trials at three academic institutions in Japan. The company, it said, is also establishing new manu
Tel Aviv, Israel, June 4, 2020 - Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased to announce the closing of a Series B equity financing of $26 million. Investors in the round included a mix of existing investors from previous rounds, such as Shavit Capital, Medison Ventures, and OurCrowd, who continue to demonstrate support for the clinical development of Alpha DaRT, as well as a number of new private and family office investors, primarily from Israel and North America. During the last year, Alpha Tau successfully completed its first-in-human clinical trial of Alpha DaRT with squamous cell carcinoma patients from Italy and Israel. The im
Introduction When 78-year-old Israeli cancer patient Lela Parnes stumbled upon the Alpha DaRT treatment in 2017, with information from a friend of hers, she had just received her third diagnosis of cancer in multiple organs, as part of a long journey that had started in 2013. Lela’s Cancer Treatment Journey Lela had first been diagnosed with cancer in 2013, as a pensionaire enjoying life with her 4 children and 9 grandchildren. Back then, a tumor was detected on her right kidney. After participating in a clinical trial for an experimental therapy that failed, she had her kidney removed. Only a few months after her surgery, another tumor was detected in her right lung and in her hip bones. Th